πŸ‡ΊπŸ‡Έ FDA
Patent

US 8188061

RNAi modulation of APOB and uses thereof

granted A61KA61K31/7105A61K31/718

Quick answer

US patent 8188061 (RNAi modulation of APOB and uses thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue May 29 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K31/7105, A61K31/718, A61P, A61P3/00